N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells Source: Eur Respir J 2003; 22: 43-49 Year: 2003
Effects of glucocorticoids on activation of extracellular signal-regulated kinases (ERK) in human pulmonary endothelial cells Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001
Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling Source: Eur Respir J 2005; 26: Suppl. 49, 713s Year: 2005
Effect of PDE4 inhibitors on MAPK activation and IL-8 production on A549 cells following the induction of oxidative stress Source: Eur Respir J 2005; 26: Suppl. 49, 99s Year: 2005
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011
Effects of budesonide on p38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Activation of ERK and AKT kinase by ventilation in an animal model of prolonged stretch due to exogenous surfactant Source: Eur Respir J 2003; 22: Suppl. 45, 210s Year: 2003
Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005
MAPK inhibition modulates Hsp27 phosphorylation and glutathione in lung epithelial cells Source: Eur Respir J 2006; 28: Suppl. 50, 192s Year: 2006
LSC 2010 Abstract: Mesothelioma cell proliferation is controlled by mitogen activated protein kinase Erk1/2 and p38 and subsequent C/EBP-β activation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
Exposure to LPS induces the upregulation of p38 MAPK in human bronchial epithelium in vivo Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003
Effects of TGF-beta and budesonide on MAPK phosphorylation, IL-6/IL-11 secretion, and cell proliferation in human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 662s Year: 2006
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005
Thrombin induces epithelial-mesenchymal transition via PAR1, PKC and ERK1/2 pathways in A549 cells Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Inhibition of GM-CSF generation in human alveolar macrophages by reduction of histone acetylation and by dephosphorylation of p38 MAPK and MKK-1 Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001
N-Acetylcysteine inhibits eotaxin and MCP-1 release in human airway smooth muscle cells in vitro through the inhibition of ROS production, resulting in a decrease of p38 MAP kinase activation Source: Eur Respir J 2002; 20: Suppl. 38, 170s Year: 2002
Transforming growth factor-β inhibition of lung fibroblast proliferation is mediated through prostaglandin E2 , via activation of p38 mitogen-activated protein kinase Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005
Stimulation of NOD1 induces RIP2, TAK1 and p38 MAPK dependent pro-inflammatory signalling in human lung microvascular endothelial cells Source: Annual Congress 2011 - Mechanisms of acute lung injury and mesenchymal cell treatment Year: 2011